{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:35:03Z","timestamp":1771335303054,"version":"3.50.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are two neuropeptides that contribute to the regulation of intestinal motility and secretion, exocrine and endocrine secretions, and homeostasis of the immune system. Their biological effects are mediated by three receptors named VPAC1, VPAC2 and PAC1 that belong to class B GPCRs. VIP and PACAP receptors have been identified as potential therapeutic targets for the treatment of chronic inflammation, neurodegenerative diseases and cancer. However, pharmacological use of endogenous ligands for these receptors is limited by their lack of specificity (PACAP binds with high affinity to VPAC1, VPAC2 and PAC1 receptors while VIP recognizes both VPAC1 and VPAC2 receptors), their poor oral bioavailability (VIP and PACAP are 27- to 38-amino acid peptides) and their short half-life. Therefore, the development of non-peptidic small molecules or specific stabilized peptidic ligands is of high interest. Structural similarities between VIP and PACAP receptors are major causes of difficulties in the design of efficient and selective compounds that could be used as therapeutics. In this study we performed structure-based virtual screening against the subset of the ZINC15 drug library. This drug repositioning screen provided new applications for a known drug: ticagrelor, a P2Y12 purinergic receptor antagonist. Ticagrelor inhibits both VPAC1 and VPAC2 receptors which was confirmed in VIP-binding and calcium mobilization assays. A following analysis of detailed ticagrelor binding modes to all three VIP and PACAP receptors with molecular dynamics revealed its allosteric mechanism of action. Using a validated homology model of inactive VPAC1 and a recently released cryo-EM structure of active VPAC1 we described how ticagrelor could block conformational changes in the region of \u2018tyrosine toggle switch\u2019 required for the receptor activation. We also discuss possible modifications of ticagrelor comparing other P2Y12 antagonist \u2013 cangrelor, closely related to ticagrelor but not active for VPAC1\/VPAC2. This\u00a0comparison with inactive cangrelor could lead to further improvement of the ticagrelor activity and selectivity for VIP and PACAP receptor sub-types.<\/jats:p>","DOI":"10.3389\/fendo.2021.711906","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:09:31Z","timestamp":1637219371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors"],"prefix":"10.3389","volume":"12","author":[{"given":"Ingrid","family":"Langer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Latek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.9224","article-title":"Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int J Biol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000906","article-title":"Drug Repositioning in Oncology","volume":"28","author":"Serafin","year":"2021","journal-title":"Am J Ther"},{"key":"B3","article-title":"Clinical Trial Failures and Drug Repositioning","volume-title":"Bioinformatics and Computational Biology in Drug Discovery and Development","author":"Crawford","year":"2016"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs as Cancer Therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"170029","DOI":"10.1038\/sdata.2017.29","article-title":"Data Descriptor: A Standard Database for Drug Repositioning Background & Summary","volume":"4","author":"Brown","year":"2017","journal-title":"Sci Data"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbz176","article-title":"Biomedical Data and Computational Models for Drug Repositioning: A Comprehensive Review","volume":"22","author":"Luo","year":"2021","journal-title":"Brief Bioinform"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/cb600362d","article-title":"Inhibition of Angiogenesis by the Antifungal Drug Itraconazole","volume":"2","author":"Chong","year":"2007","journal-title":"ACS Chem Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved Antiviral Drugs Over the Past 50 Years","volume":"29","author":"de Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and Biological Activities of Iododeoxyuridine, an Analog of Thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"BBA - Biochim Biophys Acta"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-109-27169","article-title":"Clinical Cure of Herpes Simplex Keratitis by 5-Iodo-2\u2032-Deoxyuridine","volume":"109","author":"Kaufman","year":"1962","journal-title":"Proc Soc Exp Biol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical Trials on Drug Repositioning for COVID-19 Treatment","volume":"44","author":"Viveiros Rosa","year":"2020","journal-title":"Rev Panam Salud Publica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13321-020-00450-7","article-title":"A Review of Computational Drug Repositioning: Strategies, Approaches, Opportunities, Challenges, and Directions","volume":"12","author":"Jarada","year":"2020","journal-title":"J Cheminform"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.04.004","article-title":"Drug Repositioning or Target Repositioning: A Structural Perspective of Drug-Target-Indication Relationship for Available Repurposed Drugs","volume":"18","author":"Parisi","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4939-8955-3_2","article-title":"Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation","author":"Sohraby","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1038\/s41598-020-70863-9","article-title":"An Integrated Drug Repurposing Strategy for the Rapid Identification of Potential SARS-CoV-2 Viral Inhibitors","volume":"10","author":"Trezza","year":"2020","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial Intelligence, Machine Learning, and Drug Repurposing in Cancer","volume":"9","author":"Tanoli","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.46","article-title":"Computational Drug Repositioning Based on Side-Effects Mined Fromsocial Media","volume":"2016","author":"Nugent","year":"2016","journal-title":"PeerJ Comput Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"mol.117.111062","DOI":"10.1124\/mol.117.111062","article-title":"G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs","author":"Sriram","year":"2018","journal-title":"Mol Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER Database of Drugs and Side Effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: A Next-Generation Drug Library and Information Resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2018.07.003","article-title":"Repurposing Potential of 1st Generation H1-Specific Antihistamines as Anti-Filovirus Therapeutics","volume":"157","author":"Schafer","year":"2018","journal-title":"Antiviral Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01337-15","article-title":"Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/FJC.0000000000000535","article-title":"Nucleoligands-Repurposing G Protein-Coupled Receptor Ligands to Modulate Nuclear-Localized G Protein-Coupled Receptors in the Cardiovascular System","volume":"71","author":"Audet","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15028","article-title":"GPCRs in Pancreatic Adenocarcinoma: Contributors to Tumour Biology and Novel Therapeutic Targets","volume":"177","author":"Sriram","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0631-3","article-title":"Tamoxifen Mechanically Deactivates Hepatic Stellate Cells via the G Protein-Coupled Estrogen Receptor","volume":"38","author":"Cortes","year":"2019","journal-title":"Oncogene"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2419-3","article-title":"Old Drugs With New Skills: Fenoprofen as an Allosteric Enhancer at Melanocortin Receptor 3","volume":"74","author":"Montero-Melendez","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700834R","article-title":"GPR68, a Proton-Sensing GPCR, Mediates Interaction of Cancer-Associated Fibroblasts and Cancer Cells","volume":"32","author":"Wiley","year":"2018","journal-title":"FASEB J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/molecules26040889","article-title":"Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking With A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain\/Plasma Concentration Ratio After 28 Days Multiple Doses in Rats Using LC-MS\/MS","volume":"26","author":"Ayoub","year":"2021","journal-title":"Molecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5b00500","article-title":"Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2","volume":"55","author":"Xu","year":"2015","journal-title":"J Chem Inf Model"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/154411130201300303","article-title":"Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) as Modulators of Both Innate and Adaptive Immunity","volume":"13","author":"Ganea","year":"2002","journal-title":"Crit Rev Oral Biol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-018-1150-y","article-title":"Immunomodulatory Roles of PACAP and VIP: Lessons From Knockout Mice","volume":"66","author":"Abad","year":"2018","journal-title":"J Mol Neurosci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-020-17933-8","article-title":"Cryo-EM Structure of an Activated VIP1 Receptor-G Protein Complex Revealed by a NanoBiT Tethering Strategy","volume":"11","author":"Duan","year":"2020","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-0386-8","article-title":"Cryo-EM Structure of the Human PAC1 Receptor Coupled to an Engineered Heterotrimeric G Protein","volume":"27","author":"Kobayashi","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0280-2","article-title":"Cryo-EM Structures of PAC1 Receptor Reveal Ligand Binding Mechanism","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky429","article-title":"GPCRM: A Homology Modeling Web Service With Triple Membrane-Fitted Quality Assessment of GPCR Models","volume":"46","author":"Miszta","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5b00451","article-title":"A Hybrid Approach to Structure and Function Modeling of G Protein-Coupled Receptors","volume":"56","author":"Latek","year":"2016","journal-title":"J Chem Inf Model"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056742","article-title":"Towards Improved Quality of GPCR Models by Usage of Multiple Templates and Profile-Profile Comparison","volume":"8","author":"Latek","year":"2013","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208892","article-title":"Drug-Induced Diabetes Type 2: In Silico Study Involving Class B GPCRs","volume":"14","author":"Latek","year":"2019","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210705","article-title":"Potential Off-Target Effects of Beta-Blockers on Gut Hormone Receptors: In Silico Study Including GUT-DOCK-A Web Service for Small-Molecule Docking","volume":"14","author":"Pasznik","year":"2019","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2014.06.012","article-title":"Advances in GPCR Modeling Evaluated by the GPCR Dock 2013 Assessment: Meeting New Challenges","volume":"22","author":"Kufareva","year":"2014","journal-title":"Structure"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.3390\/ijms20184348","article-title":"A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism","volume":"20","author":"Latek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/jm300687e","article-title":"Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.07.057","article-title":"From ATP to AZD6140: The Discovery of an Orally Active Reversible P2Y12 Receptor Antagonist for the Prevention of Thrombosis","volume":"17","author":"Springthorpe","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0904327","article-title":"Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S190426","article-title":"Strategic Approach to Developing a Self-Microemulsifying Drug Delivery System to Enhance Antiplatelet Activity and Bioavailability of Ticagrelor","volume":"14","author":"Na","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/ijms21041391","article-title":"P2y12 Inhibition Beyond Thrombosis: Effects on Inflammation","volume":"21","author":"Mansour","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature22363","article-title":"Structure of the Full-Length Glucagon Class B G-Protein-Coupled Receptor","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature22378","article-title":"Human GLP-1 Receptor Transmembrane Domain Structure in Complex With Allosteric Modulators","volume":"546","author":"Song","year":"2017","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.3390\/ijms22084060","article-title":"Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1r Drug Discovery","volume":"22","author":"Mizera","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1249489","article-title":"Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator","volume":"344","author":"Wu","year":"2014","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611397104","article-title":"Solution Structure and Mutational Analysis of Pituitary Adenylate Cyclase-Activating Polypeptide Binding to the Extracellular Domain of PAC1-RS","volume":"104","author":"Sun","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2174\/092986712799320556","article-title":"Action of Molecular Switches in GPCRs - Theoretical and Experimental Studies","volume":"19","author":"Trzaskowski","year":"2012","journal-title":"Curr Med Chem"},{"key":"B54","unstructured":"Daylight Chemical Information Systems, Inc."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/science.132.3434.1115","article-title":"A Computer Program for Classifying Plants","volume":"132","author":"Rogers","year":"1960","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1021\/jm981072s","article-title":"Antagonists of the Platelet P(2t) Receptor: A Novel Approach to Antithrombotic Therapy","volume":"42","author":"Ingall","year":"1999","journal-title":"J Med Chem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2960-3","article-title":"Deciphering Biased Inverse Agonism of Cangrelor and Ticagrelor at P2Y 12 Receptor","volume":"76","author":"Garcia","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12719","article-title":"Competitive Mode and Site of Interaction of Ticagrelor at the Human Platelet P2Y12-Receptor","volume":"12","author":"Hoffmann","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2174\/1874467210666170110114727","article-title":"Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures","volume":"10","author":"Dore","year":"2017","journal-title":"Curr Mol Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nature17414","article-title":"Extra-Helical Binding Site of a Glucagon Receptor Antagonist","volume":"533","author":"Jazayeri","year":"2016","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2017.10.003","article-title":"Extending the Structural View of Class B GPCRs","volume":"42","author":"de Graaf","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cellsig.2004.05.009","article-title":"Mutations in the Carboxy-Terminus of the Third Intracellular Loop of the Human Recombinant VPAC1 Receptor Impair VIP-Stimulated [Ca 2+]I Increase But Not Adenylate Cyclase Stimulation","volume":"17","author":"Langer","year":"2005","journal-title":"Cell Signal"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1677\/jme.1.01717","article-title":"Effect of Inactivating Mutations on Phosphorylation and Internalization of the Human VPAC2 Receptor","volume":"34","author":"Langer","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0589-7","article-title":"Structural Insights Into Probe-Dependent Positive Allosterism of the GLP-1 Receptor","volume":"16","author":"Bueno","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nature22394","article-title":"Cryo-EM Structure of the Activated GLP-1 Receptor in Complex With a G Protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15 - Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J Chem Inf Model"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1021\/jm901137j","article-title":"New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) From Screening Libraries and for Their Exclusion in Bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J Med Chem"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00003-0","article-title":"Prediction of \u201cDrug-Likeness\u201d","volume":"54","author":"Walters","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00153","article-title":"Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function","volume":"9","author":"Peyrassol","year":"2018","journal-title":"Front Endocrinol"},{"key":"B70","unstructured":"New York, NY, USA[Computer Software]"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.24660","article-title":"CHARMM-GUI 10 Years for Biomolecular Modeling and Simulation","volume":"38","author":"Jo","year":"2017","journal-title":"J Comput Chem"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1063\/1.470648","article-title":"Constant Pressure Molecular Dynamics Simulation: The Langevin Piston Method","volume":"103","author":"Feller","year":"1995","journal-title":"J Chem Phys"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1063\/1.467468","article-title":"Constant Pressure Molecular Dynamics Algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J Chem Phys"},{"key":"B74","doi-asserted-by":"publisher","first-page":"044130","DOI":"10.1063\/5.0014475","article-title":"Scalable Molecular Dynamics on CPU and GPU Architectures With NAMD","volume":"153","author":"Phillips","year":"2020","journal-title":"J Chem Phys"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.711906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:09:35Z","timestamp":1637219375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.711906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":74,"alternative-id":["10.3389\/fendo.2021.711906"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.711906","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"711906"}}